NERV catalyst calendar

Minerva Neurosciences, Inc.

Upcoming catalysts
2
Cash runway
41.6 months
Cash & investments
$75M
Phase 3 programs
2

Minerva Neurosciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 9, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 41.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 9, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2027 Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications Trial Milestone Phase 3

Track NERV alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open NERV in the tracker

Recent history

DateEventTypePhase
August 12, 2026 8-K filed: Leadership change Corporate —
August 7, 2026 Quarterly results filed (8-K) Earnings —
May 27, 2026 8-K filed: Material agreement, Other event Corporate —
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 6, 2026 8-K filed: Other event Filing —
April 2, 2026 8-K filed: Leadership change, Reg FD disclosure, Other event Corporate —
March 11, 2026 Quarterly results filed (8-K) Earnings —
February 3, 2026 8-K filed: Reg FD disclosure, Other event Filing —
December 22, 2025 8-K filed: Leadership change Corporate —
November 19, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
October 22, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
January 12, 2024 A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia Trial Milestone Phase 1
May 26, 2020 Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia Trial Milestone Phase 3
November 21, 2019 A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder Trial Milestone Phase 2
July 7, 2017 A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers Trial Milestone Phase 1
April 20, 2017 A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.